A New Radiopharmaceutical 225Ac-DOTA-IBA in the Treatment of a Case of Bone Metastases

Abstract

Abstract α-Emitter 225Ac has been considered a candidate for targeted α-therapy. DOTA-IBA is new a precursor targeting bone metastasis. It can be used for radionuclide labeling with 225Ac. We present a case with refractory bone pain for bone metastasis, who demonstrated an excellent therapy response after 1 cycle of 225Ac-DOTA-IBA therapy. Moreover, the patient did not have any observable adverse effects.